IRAK3

Summary

IRAK3 (interleukin 1 receptor associated kinase 3, HGNC:17020) is a protein-coding gene on chromosome 12q14.3, encoding Interleukin-1 receptor-associated kinase 3 (Q9Y616). Putative inactive protein kinase which regulates signaling downstream of immune receptors including IL1R and Toll-like receptors.

This gene encodes a member of the interleukin-1 receptor-associated kinase protein family. Members of this family are essential components of the Toll/IL-R immune signal transduction pathways. This protein is primarily expressed in monocytes and macrophages and functions as a negative regulator of Toll-like receptor signaling. Mutations in this gene are associated with a susceptibility to asthma. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 11213 — RefSeq curated summary.

At a glance

• Gene–disease (curated): asthma-related traits, susceptibility to, 5 (Limited, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 129 total — 2 likely-pathogenic
• Druggable target: yes — 35 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_007199

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17020
Approved symbol	IRAK3
Name	interleukin 1 receptor associated kinase 3
Location	12q14.3
Locus type	gene with protein product
Status	Approved
Aliases	IRAK-M
Ensembl gene	ENSG00000090376
Ensembl biotype	protein_coding
OMIM	604459
Entrez	11213

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000261233, ENST00000457197, ENST00000545837, ENST00000854785, ENST00000854786, ENST00000947373, ENST00000947374

RefSeq mRNA: 2 — MANE Select: NM_007199 NM_001142523, NM_007199

CCDS: CCDS44937, CCDS8975

Canonical transcript exons

ENST00000261233 — 12 exons

Exon	Start	End
ENSE00000871820	66203711	66203893
ENSE00000871821	66209456	66209520
ENSE00000871822	66210147	66210201
ENSE00000871825	66211446	66211597
ENSE00000871827	66217171	66217235
ENSE00000871829	66226723	66226837
ENSE00000871830	66228252	66228370
ENSE00000871832	66244486	66244684
ENSE00000871833	66244948	66245010
ENSE00000871834	66245098	66245262
ENSE00000871835	66247695	66254622
ENSE00002237551	66189214	66189432

Expression profiles

Bgee: expression breadth ubiquitous, 238 present calls, max score 94.76.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.1391 / max 2573.3421, expressed in 1183 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
126544	16.6855	1182
126546	0.8425	104
126545	0.4489	81
126547	0.0954	28
126548	0.0669	20

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	94.76	gold quality
mononuclear cell	CL:0000842	94.17	gold quality
leukocyte	CL:0000738	93.74	gold quality
bone marrow	UBERON:0002371	90.98	gold quality
parietal pleura	UBERON:0002400	90.75	gold quality
blood	UBERON:0000178	90.14	gold quality
right lung	UBERON:0002167	89.84	gold quality
bone marrow cell	CL:0002092	89.68	gold quality
bone element	UBERON:0001474	89.05	gold quality
palpebral conjunctiva	UBERON:0001812	88.42	gold quality
pleura	UBERON:0000977	88.05	gold quality
spleen	UBERON:0002106	87.89	gold quality
lower lobe of lung	UBERON:0008949	87.81	gold quality
trabecular bone tissue	UBERON:0002483	87.16	gold quality
calcaneal tendon	UBERON:0003701	86.66	gold quality
omental fat pad	UBERON:0010414	86.55	gold quality
peritoneum	UBERON:0002358	86.45	gold quality
adipose tissue of abdominal region	UBERON:0007808	86.37	gold quality
upper lobe of lung	UBERON:0008948	85.39	gold quality
upper lobe of left lung	UBERON:0008952	85.37	gold quality
granulocyte	CL:0000094	85.27	gold quality
visceral pleura	UBERON:0002401	84.76	gold quality
subcutaneous adipose tissue	UBERON:0002190	84.21	gold quality
lung	UBERON:0002048	84.06	gold quality
adipose tissue	UBERON:0001013	83.88	gold quality
connective tissue	UBERON:0002384	83.62	gold quality
epithelium of nasopharynx	UBERON:0001951	82.91	gold quality
left uterine tube	UBERON:0001303	82.07	gold quality
descending thoracic aorta	UBERON:0002345	81.94	gold quality
pericardium	UBERON:0002407	81.40	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	25.52
E-ANND-3	yes	21.25
E-CURD-11	no	101.69

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF3, JUN, NR3C1, STAT3

miRNA regulators (miRDB)

210 targeting IRAK3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-3605-5P	99.96	67.12	932

Literature-anchored findings (GeneRIF, showing 40)

• Identification and characterization of murine IRAK-M (PMID:12054681)
• Thus, our data indicate that IRAK-M could play a pivotal role in the process of endotoxin tolerance in human monocytes and provide evidence that PI3K is involved in regulating its expression. (PMID:14592437)
• IRAK-M is rapidly upregulated in human monocytes pre-exposed to tumor cells and could be involved in deactivation of tumor-infiltrating monocytes mediated by tumor cells. (PMID:15728517)
• These findings indicate that IRAK-M selectively attenuates p38 activation and inhibits innate immunity through stabilizing MKP-1. (PMID:17379480)
• IRAK-M is involved in the pathogenesis of early-onset persistent asthma. (PMID:17503328)
• no evidence to suggest association between inflammatory bowel disease, Crohn’s disease (CD), ulcerative colitis (UC) or subsets of CD & UC and IRAK-M; an interaction was found between IRAK-M and CARD15 in UC patients (PMID:17558906)
• LPS tolerance in human endotoxemia models is associated with IRAK-M up-regulation. (PMID:17982103)
• Porphyromonas gingivalis lipopolysaccharide upregulates IRAK-M in macrophages. (PMID:18156187)
• observed striking up-regulation of IRAK-M in monocytes, but without concomitant proinflammatory cytokine production (PMID:18354163)
• Analysis of single single nucleotide polymorphisms and haplotypes did not reveal a significant association between polymorphisms in the IRAK-M gene and atopic dermatitis in this cohort. (PMID:19013233)
• Immunosuppression in sepsis caused by B. pseudomallei is associated with an upregulation of IRAK-M and an indicator of poor outcome. (PMID:19114913)
• IRAK-M is a major mediator of globular adiponectin-induced endotoxin tolerance in primary macrophages (PMID:19414798)
• Nine SNPs distributed across eight genetic regions (ALOX5, IRAK3, ITGB2, NCF2, NFKB1, SELP, SOD1, and STAT1) were associated with risk of glioma with P value of <0.01. (PMID:19423540)
• inhibition of LPS-induced NFKB and ERK activation by acute alcohol leads to hyporesponsiveness of monocytes to LPS due to increased IRAK-M; chronic alcohol sensitizes monocytes to LPS through decreased IRAK-M expression and activation of NFKB and ERK (PMID:19561104)
• Intact IRAK-M is strongly expressed in resting human alveolar macrophages but is cleaved in patients with pneumonia via neutrophil-mediated induction of caspase-6 (CASP-6) activity. (PMID:21098228)
• Data demonstrates that TGF-beta-dependent induction of IRAK-M expression is an important, clinically relevant mechanism by which tumors may circumvent anti-tumor responses of macrophages. (PMID:21278795)
• Common SNPs in the IRAK3 gene may be determinants of sepsis-induced acute lung injury. (PMID:21297081)
• The upregulation of IRAK-M in macrophages is involved in the local immunosuppression around implants, and may contribute to septic and aseptic implant loosening. (PMID:21987497)
• The results confirm the importance of the IRAK3 in asthma pathogenesis in the European populations (PMID:22070913)
• these data indicate that epithelial IRAK-M overexpression in T(H)2 cytokine-exposed airways inhibits TLR2 signaling, providing a novel mechanism for the increased susceptibility of infections in asthmatic patients. (PMID:22154382)
• Data suggest further evaluation of IRAK3 as a diagnostic and prognostic marker, and as a target for intervention. (PMID:22272346)
• the tested variations of IRAK-M and SIGIRR genes do not confer a relevant role in the susceptibility to systemic lupus erythematosus in European-descent populations (PMID:22634523)
• these data identify an important signaling regulator in human macrophages that is used by surfactant to control the long-term alveolar inflammatory response, i.e., enhanced IRAK-M activity. (PMID:22886503)
• IRAK-M mediates TLR7-induced MEKK3-dependent second wave NFjB activation to produce inhibitory molecules (PMID:23376919)
• our study demonstrates that patients carrying IRAK-M+22148 G haplotype are more susceptible to sepsis than patients carrying IRAK-M+22148 A haplotype, suggesting that IRAK-M+22148 G haplotype might be a risk factor for sepsis. (PMID:23588345)
• These data indicate the enhancing effect of IRAK-M on epithelial human rhinovirus-16 infection, which is partly through the autophagic pathway. (PMID:24074582)
• The structure function of the death domain of human IRAK-M (PMID:25481771)
• IRAK-M expression is upregulated in peripheral blood cells from idiopathic pulmonary fibrosis patients (PMID:25595781)
• HIF1alpha is a regulator of monocyte functional re-programming in sepsis via regulating IRAKM expression. (PMID:25746953)
• IRAK3 methylation was associated with tumor stage and poor prognosis of hepatocellular carcinoma patients. (PMID:25852282)
• Alpha-Melanocyte-Stimulating Hormone Suppresses TLR2-Mediated Functional Responses through IRAK-M in Normal Human Keratinocytes (PMID:26309029)
• Data indicate a strong positive correlation between interleukin-1 receptor-associated kinase 3 (IRAK-M) and pSTAT3 protein in colorectal cancer (CRC). (PMID:27150039)
• Rs11541076 in IRAK3, a negative regulator of TLR signalling, as a predictor of anti-TNF treatment response. (PMID:27698401)
• IRAK-M functions to modulate inflammatory signaling pathways and is critical in maintaining immune system homeostasis in the gut. However, increased IRAK-M is associated with increased disease pathogenesis and increased cancer severity in human patients. (PMID:27939424)
• MERS-CoV S protein binds to DPP4 to suppress macrophage activation via induction of IRAK-M, PPARgamma and the immunosuppressive cytokine IL-10. (PMID:28118607)
• Clinical trial with house dust mite allergen challenge of asthmatic patients reveal that IRAK-M is a PIN1 target critical for IL-33 signaling in allergic asthma. NMR analysis and docking simulations suggest that PIN1 might regulate IRAK-M conformation and function in IL-33 signaling. (PMID:29686383)
• Study determined that the expression of a novel circRNA, circIRAK3, was increased in metastatic breast cancer (BC) cells and predictive of BC recurrence and identified miR-3607 as a circIRAK3-associated miRNA. FOXC1 the target of miR-3607, was downregulated in circIRAK3-silenced cells and mediated circIRAK3-induced BC cell migration. FOXC1 in turn could bind to the IRAK3 promoter, triggering a positive-feedback loop. (PMID:29803789)
• TLR stimulation led to IRAKM-caspase-8-ASC complex formation, resulting in the activation of caspase-8 and IL-1beta release in microglia. (PMID:30372424)
• Findings demonstrated a distinctive role of IRAK-M in maintaining chronic Th2 airway inflammation and indicated a complex role for IRAK-M in the initiation and progression of experimental allergic asthma. (PMID:30617222)
• IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity. (PMID:31664109)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	irak3	ENSDARG00000053131
mus_musculus	Irak3	ENSMUSG00000020227
rattus_norvegicus	Irak3	ENSRNOG00000004226
drosophila_melanogaster	pll	FBGN0010441
drosophila_melanogaster	Haspin	FBGN0046706
caenorhabditis_elegans		WBGENE00004029
caenorhabditis_elegans	hasp-1	WBGENE00007258
caenorhabditis_elegans		WBGENE00012159
caenorhabditis_elegans	hasp-2	WBGENE00021214

Paralogs (4): IRAK2 (ENSG00000134070), HASPIN (ENSG00000177602), IRAK1 (ENSG00000184216), IRAK4 (ENSG00000198001)

Protein

Protein identifiers

Interleukin-1 receptor-associated kinase 3 — Q9Y616 (reviewed: Q9Y616)

Alternative names: IL-1 receptor-associated kinase M, Inactive IL-1 receptor-associated kinase 3

All UniProt accessions (2): Q9Y616, F5GYN6

UniProt curated annotations — full annotation on UniProt →

Function. Putative inactive protein kinase which regulates signaling downstream of immune receptors including IL1R and Toll-like receptors. Inhibits dissociation of IRAK1 and IRAK4 from the Toll-like receptor signaling complex by either inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor complex. Upon IL33-induced lung inflammation, positively regulates expression of IL6, CSF3, CXCL2 and CCL5 mRNAs in dendritic cells.

Subunit / interactions. Monomer. Homodimer; disulfide-linked. May interact with IRAK4 (when phosphorylated). Interacts (when phosphorylated at Ser-110) with PIN1 (via WW domain) in response to IL33-mediated (but not TLR4 ligand LPS) dendritic cell stimulation.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed in eosinophils, dendritic cells and/or monocytes (at protein level). Expressed predominantly in peripheral blood lymphocytes.

Disease relevance. Asthma-related traits 5 (ASRT5) [MIM:611064] Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, dyspnea, bronchial hyperresponsiveness as assessed by methacholine challenge test, serum IgE levels, atopy and atopic dermatitis. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Domain organisation. The nucleotide binding domain binds ATP with low affinity.

Similarity. Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. Pelle subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y616-1	1	yes
Q9Y616-2	2

RefSeq proteins (2): NP_001135995, NP_009130* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000488	Death_dom	Domain
IPR000719	Prot_kinase_dom	Domain
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR011029	DEATH-like_dom_sf	Homologous_superfamily
IPR042698	IRAK3_PK	Domain
IPR042747	IRAK3_death	Domain

Pfam: PF00069, PF00531

UniProt features (73 total): helix 22, sequence variant 15, strand 14, mutagenesis site 5, binding site 4, domain 2, modified residue 2, disulfide bond 2, turn 2, chain 1, splice variant 1, region of interest 1, sequence conflict 1, site 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6ZIW	X-RAY DIFFRACTION	2.18
6RUU	X-RAY DIFFRACTION	2.95
5UKE	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y616-F1	71.79	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 110–111 (cis/trans isomerization of proline peptide bond; by pin1; dependent on ser-110 phosphorylation)

Ligand- & substrate-binding residues (4): 171–179; 192; 295–298; 311

Post-translational modifications (2): 467, 110

Disulfide bonds (2): 202, 287

Mutagenesis-validated functional residues (5):

Position	Phenotype
110	abolishes phosphorylation. abolishes interaction with pin1. reduces protein stability.
110	phosphomimic. slight decrease in the interaction with pin1. weak interaction with pin1 in absence of il33-mediated dendr
210	abolishes dimerization.
214	enhances dimerization.
467	no effect on the interaction with pin1.

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane
R-HSA-9020702	Interleukin-1 signaling
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade
R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-168898	Toll-like Receptor Cascades
R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade
R-HSA-446652	Interleukin-1 family signaling
R-HSA-449147	Signaling by Interleukins

MSigDB gene sets: 305 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_TOLERANCE_INDUCTION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_NEGATIVE_REGULATION_OF_PRODUCTION_OF_MOLECULAR_MEDIATOR_OF_IMMUNE_RESPONSE, CHUNG_BLISTER_CYTOTOXICITY_DN, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, PID_IL1_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_CYTOKINE_PRODUCTION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_INNATE_IMMUNE_RESPONSE, GOBP_NEGATIVE_REGULATION_OF_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY

GO Biological Process (30): positive regulation of cytokine production (GO:0001819), negative regulation of cytokine-mediated signaling pathway (GO:0001960), MyD88-dependent toll-like receptor signaling pathway (GO:0002755), protein phosphorylation (GO:0006468), Toll signaling pathway (GO:0008063), response to virus (GO:0009615), positive regulation of macrophage tolerance induction (GO:0010933), negative regulation of macrophage cytokine production (GO:0010936), cytokine-mediated signaling pathway (GO:0019221), lipopolysaccharide-mediated signaling pathway (GO:0031663), response to peptidoglycan (GO:0032494), response to lipopolysaccharide (GO:0032496), negative regulation of interleukin-12 production (GO:0032695), negative regulation of interleukin-6 production (GO:0032715), negative regulation of tumor necrosis factor production (GO:0032720), negative regulation of toll-like receptor signaling pathway (GO:0034122), intracellular signal transduction (GO:0035556), negative regulation of protein catabolic process (GO:0042177), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), negative regulation of canonical NF-kappaB signal transduction (GO:0043124), negative regulation of protein-containing complex disassembly (GO:0043242), regulation of protein-containing complex disassembly (GO:0043244), response to exogenous dsRNA (GO:0043330), negative regulation of MAPK cascade (GO:0043409), negative regulation of innate immune response (GO:0045824), interleukin-1-mediated signaling pathway (GO:0070498), response to interleukin-1 (GO:0070555), positive regulation of immune system process (GO:0002684), signal transduction (GO:0007165), regulation of innate immune response (GO:0045088)

GO Molecular Function (9): magnesium ion binding (GO:0000287), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein kinase binding (GO:0019901), protein homodimerization activity (GO:0042803), protein heterodimerization activity (GO:0046982), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), plasma membrane (GO:0005886)

Reactome top-level categories

Rollup of top-10 pathways:

Category	Pathways
Immune System	2
Toll-like Receptor Cascades	2
Toll Like Receptor 2 (TLR2) Cascade	2
Toll Like Receptor 4 (TLR4) Cascade	1
Toll Like Receptor TLR1:TLR2 Cascade	1
Toll Like Receptor TLR6:TLR2 Cascade	1
Interleukin-1 family signaling	1
Innate Immune System	1
Signaling by Interleukins	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell surface receptor signaling pathway	3
negative regulation of signal transduction	2
toll-like receptor signaling pathway	2
response to molecule of bacterial origin	2
response to oxygen-containing compound	2
negative regulation of cytokine production	2
intracellular anatomical structure	2
canonical NF-kappaB signal transduction	2
regulation of canonical NF-kappaB signal transduction	2
protein dimerization activity	2
cytokine production	1
regulation of cytokine production	1
positive regulation of gene expression	1
positive regulation of multicellular organismal process	1
regulation of cytokine-mediated signaling pathway	1
cytokine-mediated signaling pathway	1
negative regulation of response to cytokine stimulus	1
phosphorylation	1
protein modification process	1
response to other organism	1
positive regulation of tolerance induction	1
macrophage tolerance induction	1
regulation of macrophage tolerance induction	1
negative regulation of cytokine production involved in immune response	1
macrophage cytokine production	1
regulation of macrophage cytokine production	1
cellular response to cytokine stimulus	1
cellular response to lipopolysaccharide	1
response to nitrogen compound	1
response to lipid	1
interleukin-12 production	1
regulation of interleukin-12 production	1
interleukin-6 production	1
regulation of interleukin-6 production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
negative regulation of tumor necrosis factor superfamily cytokine production	1
negative regulation of immune system process	1
regulation of toll-like receptor signaling pathway	1
signal transduction	1

Protein interactions and networks

STRING

2322 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IRAK3	IRAK1	P51617	984
IRAK3	IRAK2	O43187	974
IRAK3	IRAK4	Q9NWZ3	947
IRAK3	MYD88	P78397	924
IRAK3	TRAF6	Q9Y4K3	863
IRAK3	SIGIRR	Q6IA17	843
IRAK3	IL1R1	P14778	781
IRAK3	TLR4	O00206	774
IRAK3	TLR2	O60603	770
IRAK3	INPP5D	Q92835	736
IRAK3	TOLLIP	Q9H0E2	707
IRAK3	TLR5	O60602	664
IRAK3	TLR9	Q9NR96	660
IRAK3	TLR3	O15455	647
IRAK3	TLR8	Q9NR97	645

IntAct

33 interactions, top by confidence:

A	B	Type	Score
TRAF6	IRAK3	psi-mi:“MI:0915”(physical association)	0.680
IRAK3	TRAF6	psi-mi:“MI:0915”(physical association)	0.680
IRAK1	IRAK3	psi-mi:“MI:0915”(physical association)	0.560
IRAK2	IRAK3	psi-mi:“MI:0915”(physical association)	0.560
IRAK3	IRAK1	psi-mi:“MI:0915”(physical association)	0.560
IRAK3	IRAK2	psi-mi:“MI:0915”(physical association)	0.560
IRAK3	IRAK2	psi-mi:“MI:0914”(association)	0.560
IRAK3	CD14	psi-mi:“MI:0915”(physical association)	0.440
IRAK3	HOXB7	psi-mi:“MI:0915”(physical association)	0.440
IRAK3	CD14	psi-mi:“MI:0403”(colocalization)	0.440
HOXB7	IRAK3	psi-mi:“MI:0403”(colocalization)	0.440
IRAK3	KRT8	psi-mi:“MI:0915”(physical association)	0.400
IRAK3	KRT18	psi-mi:“MI:0915”(physical association)	0.400
IRAK3	MYD88	psi-mi:“MI:0915”(physical association)	0.400
IRAK3	IRAK3	psi-mi:“MI:0915”(physical association)	0.400
TICAM2	IRAK3	psi-mi:“MI:0915”(physical association)	0.400
HSP90AB1	IRAK3	psi-mi:“MI:0915”(physical association)	0.400
ATP6V0B	IRAK3	psi-mi:“MI:0915”(physical association)	0.370
IRAK3	COPB1	psi-mi:“MI:0915”(physical association)	0.370
IRAK3	ECM1	psi-mi:“MI:0915”(physical association)	0.370
FOLR1	IRAK3	psi-mi:“MI:0915”(physical association)	0.370
IRAK3	CDCA5	psi-mi:“MI:0915”(physical association)	0.370
IRAK3	ADH1B	psi-mi:“MI:0915”(physical association)	0.370
NONO	IRAK3	psi-mi:“MI:0915”(physical association)	0.370
NTRK3	IRAK3	psi-mi:“MI:0915”(physical association)	0.370
LDB1	IRAK3	psi-mi:“MI:0915”(physical association)	0.370
NSA2	IRAK3	psi-mi:“MI:0915”(physical association)	0.370
	ABL1	psi-mi:“MI:0914”(association)	0.350
IRAK3	H2AZ1	psi-mi:“MI:0914”(association)	0.350
IRAK3	CD44	psi-mi:“MI:0914”(association)	0.350

BioGRID (35): TRAF6 (Two-hybrid), IRAK3 (Proximity Label-MS), IRAK3 (Proximity Label-MS), IRAK3 (Affinity Capture-Western), IRAK3 (Affinity Capture-Western), RNF152 (Affinity Capture-Western), IRAK3 (Proximity Label-MS), IRAK3 (Affinity Capture-Western), CD44 (Affinity Capture-MS), DPP8 (Affinity Capture-MS), FKBP5 (Affinity Capture-MS), TBK1 (Affinity Capture-MS), HSPB8 (Affinity Capture-MS), H2AFZ (Affinity Capture-MS), HIST2H2AC (Affinity Capture-MS)

ESM2 similar proteins: A4Q9F4, A6QLH5, D3Z7P3, D3ZVU9, E9PV86, M0R7T9, O35652, O43414, O54804, O60242, O60347, O70512, O94925, P08887, P0C7M8, P13264, P35790, P85298, Q01134, Q08DW9, Q13202, Q13505, Q2HJ53, Q2TBM7, Q3UGX3, Q4R766, Q4R7M4, Q58DH2, Q5XI70, Q62225, Q6AYT7, Q6DN14, Q80T74, Q80UW0, Q80ZF8, Q86W50, Q8C460, Q8N2K0, Q8NBA8, Q8NHH1

Diamond homologs: A0A0P0XII1, C0LGD7, C0LGG7, C0LGU1, C0LGU5, D7UPN3, F4JEQ2, F4JPX3, G5ECP4, O22187, O22476, O43187, O48814, O49839, O49840, O65472, O65530, O80719, O80939, P43293, P46573, P51617, P93050, Q05652, Q06548, Q0P5I2, Q0WRY5, Q1PDV6, Q1PDW3, Q1PE89, Q1PEM5, Q1RMT8, Q2LGB3, Q39086, Q3E9X6, Q3EDL4, Q5PP29, Q5R810, Q5WA76, Q5XF79

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
IRAK3	down-regulates	IRAK4	binding
NR3C1	“up-regulates quantity”	IRAK3	“transcriptional regulation”
IRAK3	“down-regulates activity”	Inflammation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 24 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	6	54.4×	1e-07
MyD88 dependent cascade initiated on endosome	6	54.4×	1e-07
Toll Like Receptor 7/8 (TLR7/8) Cascade	5	43.9×	4e-06
Toll Like Receptor 9 (TLR9) Cascade	5	41.8×	5e-06
MyD88:MAL(TIRAP) cascade initiated on plasma membrane	5	36.2×	8e-06
Toll Like Receptor 4 (TLR4) Cascade	5	31.2×	1e-05
Toll-like Receptor Cascades	5	29.6×	2e-05
Cytokine Signaling in Immune system	5	9.7×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
toll-like receptor 4 signaling pathway	6	131.7×	2e-09
positive regulation of type I interferon production	5	87.8×	4e-07
positive regulation of canonical NF-kappaB signal transduction	8	24.2×	2e-07
cellular response to lipopolysaccharide	5	20.4×	2e-04
inflammatory response	6	9.4×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

129 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	2
Uncertain significance	93
Likely benign	13
Benign	6

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
423059	NM_007199.3(IRAK3):c.1218_1219insTGA (p.Val407Ter)	Likely pathogenic
503865	NM_007199.3(IRAK3):c.1148dup (p.Arg384fs)	Likely pathogenic

SpliceAI

2928 predictions. Top by Δscore:

Variant	Effect	Δscore
12:66203700:A:AG	acceptor_gain	1.0000
12:66203701:A:G	acceptor_gain	1.0000
12:66210144:TAG:T	acceptor_loss	1.0000
12:66210145:A:AG	acceptor_gain	1.0000
12:66210145:AGG:A	acceptor_loss	1.0000
12:66210146:G:GG	acceptor_gain	1.0000
12:66210198:AAAG:A	donor_loss	1.0000
12:66210199:AAGG:A	donor_loss	1.0000
12:66210200:AGG:A	donor_loss	1.0000
12:66210201:GGTAT:G	donor_loss	1.0000
12:66210202:G:GA	donor_loss	1.0000
12:66210203:T:G	donor_loss	1.0000
12:66211444:A:G	acceptor_gain	1.0000
12:66217236:G:GG	donor_gain	1.0000
12:66245095:AAGC:A	acceptor_gain	1.0000
12:66245095:AAGCG:A	acceptor_gain	1.0000
12:66189431:GG:G	donor_gain	0.9900
12:66189432:GG:G	donor_gain	0.9900
12:66189432:GGTG:G	donor_loss	0.9900
12:66189433:G:GA	donor_loss	0.9900
12:66189434:T:G	donor_loss	0.9900
12:66190115:T:G	donor_gain	0.9900
12:66209491:G:GT	donor_gain	0.9900
12:66209492:A:T	donor_gain	0.9900
12:66210142:CTTA:C	acceptor_loss	0.9900
12:66210145:AG:A	acceptor_gain	0.9900
12:66210146:GG:G	acceptor_gain	0.9900
12:66211443:A:AG	acceptor_gain	0.9900
12:66211443:AAG:A	acceptor_gain	0.9900
12:66244550:C:CA	acceptor_gain	0.9900

AlphaMissense

3948 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:66189420:T:A	W41R	0.996
12:66189420:T:C	W41R	0.996
12:66203834:T:C	L86P	0.993
12:66245247:A:C	R433S	0.990
12:66245247:A:T	R433S	0.990
12:66189422:G:C	W41C	0.988
12:66189422:G:T	W41C	0.988
12:66228273:T:A	W264R	0.988
12:66228273:T:C	W264R	0.988
12:66245246:G:C	R433T	0.988
12:66203806:G:C	A77P	0.987
12:66189396:G:C	D33H	0.986
12:66203776:A:C	S67R	0.986
12:66203778:T:A	S67R	0.986
12:66203778:T:G	S67R	0.986
12:66203795:T:C	L73P	0.986
12:66203846:T:C	L90P	0.984
12:66228283:G:C	R267P	0.984
12:66245221:T:C	C425R	0.983
12:66189417:G:C	G40R	0.982
12:66203783:C:A	T69K	0.982
12:66203797:T:A	W74R	0.980
12:66203797:T:C	W74R	0.980
12:66244680:G:A	G361E	0.979
12:66189430:T:C	L44P	0.978
12:66245245:A:G	R433G	0.978
12:66244673:A:C	S359R	0.977
12:66244675:C:A	S359R	0.977
12:66244675:C:G	S359R	0.977
12:66211585:A:C	K192N	0.976

dbSNP variants (sampled 300 via entrez): RS1000027530 (12:66236547 G>A), RS1000177646 (12:66235857 C>T), RS1000209533 (12:66238992 A>T), RS1000245350 (12:66187870 T>C), RS1000333745 (12:66242043 G>A,C,T), RS1000341406 (12:66232063 C>T), RS1000370917 (12:66219183 G>T), RS1000396243 (12:66224993 A>C), RS1000579389 (12:66222905 A>G), RS1000616881 (12:66229781 C>T), RS1000627962 (12:66235541 C>G), RS1000672279 (12:66231725 A>T), RS1000673079 (12:66230388 T>C), RS1000690764 (12:66229178 C>G), RS1000785344 (12:66228688 A>C)

Disease associations

OMIM: gene MIM:604459 | disease phenotypes: MIM:142623, MIM:611064

GenCC curated gene-disease

Disease	Classification	Inheritance
asthma-related traits, susceptibility to, 5	Limited	Autosomal dominant

Mondo (2): Hirschsprung disease, susceptibility to, 1 (MONDO:0007723), asthma-related traits, susceptibility to, 5 (MONDO:0012607)

Orphanet (1): Hirschsprung disease (Orphanet:388)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002361_26	Smooth-surface caries	3.000000e-07
GCST005976_21	White blood cell count (basophil)	2.000000e-10
GCST011398_6	Response to esketamine in treatment resistant depression	4.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005090	basophil count
EFO:0009748	response to ketamine

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL4742326 (PROTEIN-PROTEIN INTERACTION), CHEMBL4748234 (PROTEIN-PROTEIN INTERACTION), CHEMBL5081 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

35 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 279,917 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL2035187	PACRITINIB	4	3,345
CHEMBL2103830	FOSTAMATINIB	4	3,841
CHEMBL3301622	GILTERITINIB	4	2,395
CHEMBL477772	PAZOPANIB	4	15,540
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL601719	CRIZOTINIB	4	14,403
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL939	GEFITINIB	4	117,814
CHEMBL2105728	CRENOLANIB	3	2,167
CHEMBL31965	CANERTINIB	3	8,083
CHEMBL603469	LESTAURTINIB	3
CHEMBL1230609	FORETINIB	2	3,096
CHEMBL1236962	OMIPALISIB	2	3,989
CHEMBL124660	TANDUTINIB	2	2,530
CHEMBL1721885	SU-014813	2	363
CHEMBL1822792	MK-2461	2	686
CHEMBL1944698	ZOTIRACICLIB	2	2,915
CHEMBL215152	DEFOSBARASERTIB	2	372
CHEMBL475251	R-406	2
CHEMBL521851	PICTILISIB	2
CHEMBL564829	MILCICLIB	2
CHEMBL572878	TOZASERTIB	2
CHEMBL1908394	GSK-461364	1
CHEMBL1908397	KW-2449	1
CHEMBL1952329	SGI-1776	1
CHEMBL259084	MLN-8054	1
CHEMBL296468	BMS-387032	1
CHEMBL3544932	TAK-901	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Interleukin-1 receptor-associated kinase (IRAK) family

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
IRAK3 PROTAC 23	Binding	8.3	pIC50

Binding affinities (BindingDB)

12 measured of 12 human assays (12 total across all organisms); most potent 12 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
Staurosporine	KD	1.7 nM
PKC-412	KD	190 nM
4-[[7-[2,6-bis(fluoranyl)phenyl]-9-chloranyl-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid	KD	300 nM
4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide	KD	740 nM
N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide	KD	1100 nM
CI-1033	KD	1700 nM
BMS-387072	KD	1800 nM
GEFITINIB	IC50	2300 nM	US-9416123: Kinase modulators for the treatment of cancer
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide	KD	2900 nM
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b	KD	3100 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM

ChEMBL bioactivities

106 potent at pChembl≥5 of 107 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.40	IC50	4	nM	CHEMBL4788568
8.40	IC50	4	nM	CHEMBL4763746
8.30	IC50	5	nM	CHEMBL4749646
8.22	IC50	6	nM	CHEMBL4744403
8.22	IC50	6	nM	CHEMBL4777817
8.22	IC50	6	nM	CHEMBL4798668
8.15	Kd	7	nM	GILTERITINIB
8.00	IC50	10	nM	CHEMBL4094760
8.00	IC50	10	nM	CHEMBL4779593
7.96	Kd	11	nM	R-406
7.95	Kd	11.24	nM	CHEMBL5653589
7.92	Kd	12	nM	CHEMBL3688339
7.89	IC50	13	nM	CHEMBL4791281
7.89	Kd	13	nM	STAUROSPORINE
7.82	IC50	15	nM	CHEMBL4754560
7.80	Kd	16	nM	LESTAURTINIB
7.72	IC50	19	nM	CHEMBL4779139
7.68	IC50	21	nM	CHEMBL4762658
7.68	IC50	21	nM	CHEMBL4757434
7.68	IC50	21	nM	CHEMBL4747690
7.66	IC50	22	nM	CHEMBL4746543
7.62	Kd	24	nM	MK-5108
7.62	IC50	24	nM	CHEMBL4763804
7.60	IC50	25	nM	CHEMBL4787051
7.58	Kd	26	nM	SGI-1776
7.58	ED50	26.22	nM	CHEMBL5653589
7.57	Kd	27	nM	TAK-901
7.57	IC50	27	nM	CHEMBL4064608
7.51	IC50	31	nM	CHEMBL4278882
7.51	Kd	31	nM	CRIZOTINIB
7.48	IC50	33	nM	CHEMBL4752190
7.48	IC50	33	nM	CHEMBL4753038
7.47	IC50	34	nM	CHEMBL4743058
7.47	Kd	34	nM	CHEMBL4749646
7.46	Kd	35	nM	PACRITINIB
7.37	Kd	43	nM	R-406
7.30	IC50	50	nM	CHEMBL4778668
7.29	IC50	51	nM	CHEMBL4750934
7.24	Kd	57	nM	CYC-116
7.10	Kd	80	nM	XL-228
7.03	Kd	93	nM	CHEMBL4064608
6.92	Kd	120	nM	FEDRATINIB
6.83	Kd	147	nM	LESTAURTINIB
6.80	Kd	160	nM	TAE-684
6.75	Kd	180	nM	MIDOSTAURIN
6.62	Kd	240	nM	KW-2449
6.59	Kd	254	nM	K-252A
6.54	Kd	291	nM	MILCICLIB
6.54	Kd	286	nM	ZOTIRACICLIB
6.43	Kd	370	nM	FORETINIB

PubChem BioAssay actives

98 with measured affinity, of 538 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-(1-methyl-2,6-dioxopiperidin-3-yl)-5-[4-[2-[1-[4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanoyl]piperidin-4-yl]ethyl]piperazin-1-yl]isoindole-1,3-dione	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0040	uM
1-[4-[4-[(5-propan-2-yl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]piperazin-1-yl]ethanone	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0040	uM
2-(2,6-dioxopiperidin-3-yl)-5-[4-[2-[1-[4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanoyl]piperidin-4-yl]ethyl]piperazin-1-yl]isoindole-1,3-dione	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0050	uM
1-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]ethanone	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0060	uM
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[7-[[4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanoyl]amino]heptanoylamino]butanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0060	uM
2-(2,6-dioxopiperidin-3-yl)-5-[4-[[1-[4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanoyl]piperidin-4-yl]methyl]piperazin-1-yl]isoindole-1,3-dione	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0060	uM
Gilteritinib	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0070	uM
N-(4-morpholin-4-ylcyclohexyl)-5-(oxan-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0100	uM
N-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethyl]-4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0100	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	625066: Binding constant for IRAK3 kinase domain	kd	0.0110	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148602: Binding affinity to human IRAK3 incubated for 45 mins by Kinobead based pull down assay	kd	0.0112	uM
1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0120	uM
N-[4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]butyl]-4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0130	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	435528: Binding constant for IRAK3 kinase domain	kd	0.0130	uM
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanoyl]amino]butanoylamino]butanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0150	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507570: Binding affinity to IRAK3	kd	0.0160	uM
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[[2-[2-[2-[2-[2-[[4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]butanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0190	uM
N-[6-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]hexyl]-4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0210	uM
N-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]-4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0210	uM
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[[2-[2-[2-[2-[2-oxo-2-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]butanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0210	uM
N-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0220	uM
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[[2-[2-[2-[[4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]butanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0240	uM
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[[2-[2-[2-[2-[[4-oxo-4-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]butanoyl]amino]ethoxy]ethoxy]ethoxy]acetyl]amino]butanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0250	uM
N-[(1-methylpiperidin-4-yl)methyl]-3-[3-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazin-6-amine	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0260	uM
5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0270	uM
Crizotinib	625066: Binding constant for IRAK3 kinase domain	kd	0.0310	uM
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[[2-[2-[2-[2-[2-[2-[2-oxo-2-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]butanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0330	uM
2-(2,6-dioxopiperidin-3-yl)-4-[2-[2-[2-[2-[2-[3-oxo-3-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]propoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]isoindole-1,3-dione	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0330	uM
2-(2,6-dioxopiperidin-3-yl)-4-[2-[2-[2-[3-oxo-3-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]propoxy]ethoxy]ethoxy]ethylamino]isoindole-1,3-dione	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0340	uM
Pacritinib	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0350	uM
2-(2,6-dioxopiperidin-3-yl)-4-[2-[2-[2-[2-[3-oxo-3-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]propoxy]ethoxy]ethoxy]ethoxy]ethylamino]isoindole-1,3-dione	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0500	uM
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[[2-[2-[2-[2-[2-[2-oxo-2-[4-[4-[(5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]cyclohexyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]butanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide	1723774: Inhibition of kinase tracer 236 binding to recombinant human full-length GST-tagged IRAK3 expressed in insect cells by Lanthascreen Eu kinase binding assay	ic50	0.0510	uM
4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0570	uM
4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-N-[(3-propan-2-yl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0800	uM
Fedratinib	625066: Binding constant for IRAK3 kinase domain	kd	0.1200	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	625066: Binding constant for IRAK3 kinase domain	kd	0.1600	uM
Midostaurin	435528: Binding constant for IRAK3 kinase domain	kd	0.1800	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	625066: Binding constant for IRAK3 kinase domain	kd	0.2400	uM
methyl (15S,16R,18R)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2540	uM
(16E)-14-methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2860	uM
N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,5-h]quinazoline-3-carboxamide	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2910	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	625066: Binding constant for IRAK3 kinase domain	kd	0.3700	uM
N-methyl-6-(trifluoromethyl)-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine	1673297: Binding affinity to human wild type partial length IRAK3 (V147 to E596 residues) expressed in bacterial expression system by Kinomescan method	kd	0.4800	uM
14-[[[(2R)-1,4-dioxan-2-yl]methyl-methylsulfamoyl]amino]-5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.5020	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148602: Binding affinity to human IRAK3 incubated for 45 mins by Kinobead based pull down assay	kd	0.5768	uM
(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one	625066: Binding constant for IRAK3 kinase domain	kd	0.6100	uM
4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide	435528: Binding constant for IRAK3 kinase domain	kd	0.7300	uM
N-[(2R)-2-fluoro-3-hydroxy-3-methylbutyl]-6-[(6-fluoropyrazolo[1,5-a]pyrimidin-5-yl)amino]-4-(propan-2-ylamino)pyridine-3-carboxamide	1664785: Inhibition of human wild type partial length IRAK3 (147 to 596 residues) expressed in bacterial expression system	ic50	0.7600	uM
4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine	1425028: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.7710	uM
Pazopanib	435528: Binding constant for IRAK3 kinase domain	kd	0.8000	uM

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	2
Vehicle Emissions	decreases expression, decreases reaction, increases expression	2
Lipopolysaccharides	increases expression	2
aristolochic acid I	decreases expression	1
trichostatin A	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
incobotulinumtoxinA	increases expression	1
(+)-JQ1 compound	decreases expression	1
Norethindrone Acetate	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Allergens	increases expression	1
Benzo(a)pyrene	increases methylation	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Formaldehyde	decreases expression	1
Hyaluronic Acid	increases expression	1
Methyl Methanesulfonate	decreases expression	1
Progesterone	increases expression	1
Silicon Dioxide	increases methylation	1
Smoke	decreases expression, increases abundance	1
Tetradecanoylphorbol Acetate	affects cotreatment, affects expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases expression	1
Vanadates	decreases expression	1
Zinc	affects cotreatment, affects expression	1

ChEMBL screening assays

147 unique, capped per target: 147 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4729440	Binding	Protac activity at CRBN/IRAK3 in LPS-induced human THP1 cells assessed as induction of IRAK3 degradation at 1 uM by Western blot analysis relative to control	Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase. — J Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B9YE	Abcam THP-1 IRAK3 KO	Cancer cell line	Male
CVCL_E0FA	Ubigene HeLa IRAK3 KO	Cancer cell line	Female
CVCL_SS86	HAP1 IRAK3 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

48 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02343562	PHASE4	UNKNOWN	Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis
NCT07186647	PHASE4	COMPLETED	Laparoscopic-Assisted Transanal Pull-Through for Hirschsprung Disease in Pediatric:Short and Intermediate Outcomes of Two Different Techniques
NCT04904081	PHASE3	UNKNOWN	Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery
NCT00630838	PHASE2	COMPLETED	Probiotic Prophylaxis of Hirschprung’s Disease Associated Enterocolitis (HAEC)
NCT01985646	EARLY_PHASE1	COMPLETED	A Trial on Conservative Treatment for Infants’ Hirschsprung Disease
NCT00478712	Not specified	RECRUITING	Hirschsprung Disease Genetic Study
NCT01515501	Not specified	COMPLETED	Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial)
NCT01793168	Not specified	RECRUITING	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT01927809	Not specified	UNKNOWN	Genetic Mosaicism in Hirschsprung’s Disease
NCT02193685	Not specified	UNKNOWN	Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease
NCT02216994	Not specified	UNKNOWN	A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis –a Prospective Study
NCT02296008	Not specified	COMPLETED	3D High Resolution Anorectal Manometry in Children After Surgery for Anorectal Disorders
NCT02776176	Not specified	UNKNOWN	Enhanced Recovery After Surgery In Hirschsprung Disease
NCT02857205	Not specified	COMPLETED	MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung’s Associated EnteroColitis
NCT03269812	Not specified	UNKNOWN	Laparoscopic Assisted Pull-through Versus Other Surgical Procedures for Treatment of Hirschsprung Disease
NCT03666767	Not specified	COMPLETED	Management and Outcomes of Congenital Anomalies in Low-, Middle- and High-Income Countries
NCT04020939	Not specified	COMPLETED	The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery.
NCT04106947	Not specified	UNKNOWN	Transition of Care for Patients With Hirschsprung Disease and Anorectal Malformations
NCT04149093	Not specified	UNKNOWN	The Association Between Calretinin and the Function of Ganglion Cells in Hirschsprung Disease
NCT04150120	Not specified	COMPLETED	eHealth as an Aid for Facilitating and Supporting Self-management in Families With Long-term Childhood Illness
NCT04213976	Not specified	UNKNOWN	Ostomy in Continuity or Conventional Ileostomy: a Retrospective Multicentric Analysis
NCT04476225	Not specified	COMPLETED	Induced Pluripotent Stem Cells for Disease Research
NCT04598841	Not specified	COMPLETED	Nutrition Support for Hirschsprung Disease
NCT04622410	Not specified	RECRUITING	Registry for Hirschsprung Disease of the BELAPS
NCT04624334	Not specified	TERMINATED	Non-invasive Assessment of Colonic Motility
NCT04730128	Not specified	COMPLETED	Translation and Validation of a Disease-specific Questionnaire for Hirschsprung’s Disease in Danish Patients
NCT04837963	Not specified	COMPLETED	Does Hirschsprung Disease Increase the Risk of Febrile Urinary Tract Infection in Children
NCT04957667	Not specified	COMPLETED	Scintigraphic Defecography for Evaluation of Functional Outcome in an Adult Hirschsprung Population
NCT05038345	Not specified	TERMINATED	Hirschsprung Disease Trends in the United States: Analysis of the National Inpatient Sample
NCT05044741	Not specified	COMPLETED	Risk Factors of Perforated HSCR in Neonates
NCT05293353	Not specified	UNKNOWN	Neokare Safety and Tolerability Assessment in Neonates With GI Problems
NCT05307419	Not specified	UNKNOWN	Full Thickness vs. Rectal Suction Biopsy in the Diagnosis of Hirschsprungs Disease
NCT05450991	Not specified	RECRUITING	Long-term Qualitative and Quantitative Outcomes of Children With Hirschsprung’s Disease and Anorectal Malformations
NCT05655845	Not specified	UNKNOWN	Risk Factors for Bowel Dysfunction at Preschool and Early Childhood Age in Children With Hirschsprung Disease
NCT06072976	Not specified	RECRUITING	The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies
NCT06197061	Not specified	UNKNOWN	Comparison of Robot-assisted With Laparoscopic-assisted Modified Soave Procedure for Classical Hirschsprung Disease
NCT06573723	Not specified	RECRUITING	Institutional Registry of Rare Diseases
NCT06590142	Not specified	RECRUITING	Hirschsprung’s Advances; Working Towards Autologous tIssue therapIes
NCT06592534	Not specified	NOT_YET_RECRUITING	Babies With Enterocolitis - A Study of Faecal Calprotectin in Hirschsprung Disease (The BEACH Study)
NCT06650683	Not specified	RECRUITING	Impact of Providing Nursing Support on Parental Stress Related to Preoperative Care of a Newborn with Hirschsprung’s Disease